Profilo
Roland Wandeler is President-Biopharma Business Unit at Grifols SA since 2024.
Former roles include Chief Executive Officer at Sundance Biosciences, Inc. from 2022 to 2023, VP, GM-US Bone Health & Cardiology Business Unit at Amgen, Inc., and Chief Operating Officer at MorphoSys AG from 2020 to 2021.
Education includes graduate and doctorate degrees from the Swiss Federal Institute of Technology.
Posizioni attive di Roland Wandeler
| Società | Posizione | Inizio |
|---|---|---|
| GRIFOLS, S.A. | Corporate Officer/Principal | 01/01/2024 |
| IDORSIA LTD | Amministratore Delegato | 01/10/2026 |
Precedenti posizioni note di Roland Wandeler
| Società | Posizione | Fine |
|---|---|---|
Encinal Bio, Inc. | Amministratore Delegato | 01/10/2023 |
| MORPHOSYS AG | Direttore operativo | 31/12/2021 |
| AMGEN INC. | Corporate Officer/Principal | - |
Formazione di Roland Wandeler
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 6 |
|---|---|
Amgen, Inc.
Amgen, Inc. BiotechnologyHealth Technology Discovers, develops, manufactures and delivers human therapeutics | Health Technology |
Grifols SA
Grifols SA Pharmaceuticals: MajorHealth Technology Develops and manufactures biopharmaceuticals, diagnostic and bio supplies | Health Technology |
MorphoSys AG
MorphoSys AG BiotechnologyHealth Technology Manufactures pharmaceutical products and provides research and development services | Health Technology |
Swiss Federal Institute of Technology
Swiss Federal Institute of Technology Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Idorsia Ltd.
Idorsia Ltd. Pharmaceuticals: MajorHealth Technology Engages in the discovery, development and commercialization of medicines for unmet medical needs | Health Technology |
Encinal Bio, Inc. |
















